Meropenem population pharmacokinetics and model-based dosing
optimisation in patients with serious bacterial infection

J 2022

Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection

MURÍNOVÁ, Irena, Martin SVIDRNOCH, Tomas GUCKY, David REZAC, Jan HLAVAC et. al.

Basic information

Original name

Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection

Authors

MURÍNOVÁ, Irena (203 Czech Republic, belonging to the institution), Martin SVIDRNOCH, Tomas GUCKY, David REZAC, Jan HLAVAC, Ondrej SLANAR and Martin SIMA (guarantor)

Edition

EUROPEAN JOURNAL OF HOSPITAL PHARMACY, London, BMJ Publishing Group, 2022, 2047-9956

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.700

RIV identification code

RIV/00216224:14160/22:00127365

Organization unit

Faculty of Pharmacy

DOI

http://dx.doi.org/10.1136/ejhpharm-2022-003535

UT WoS

000877092100001

Keywords in English

critical care; administration; intravenous; drug monitoring; pharmacy service; hospital; practice guideline

Abstract

V originále

Objectives The objective of this study was to develop a population pharmacokinetic model of meropenem in a heterogeneous population of patients with a serious bacterial infection in order to propose dosing optimisation leading to improved achievement of the pharmacokinetic/pharmacodynamic (PK/PD) target. Methods A total of 174 meropenem serum levels obtained from 144 patients during therapeutic drug monitoring were analysed using a non-linear mixed-effects modelling approach and Monte Carlo simulation was then used to compare various dosing regimens in order to optimise PK/PD target attainment. Results The meropenem volume of distribution of the patient population was 54.95 L, while clearance started at 3.27 L/hour and increased by 0.91 L/hour with each 1 mL/s/1.73 m2 of estimated glomerular filtration rate. Meropenem clearance was also 0.31 L/hour higher in postoperative patients with central nervous system infection. Meropenem administration by continuous infusion showed a significantly higher probability of attaining the PK/PD target than a standard 30 min infusion (95.3% vs 49.5%). Conclusions A daily meropenem dose of 3 g, 6 g and 10.5 g administered by continuous infusion was shown to be accurate for patients with moderate to severe renal impairment, normal renal function to mild renal impairment and augmented renal clearance, respectively

Citovat

MURÍNOVÁ, Irena, Martin SVIDRNOCH, Tomas GUCKY, David REZAC, Jan HLAVAC, Ondrej SLANAR and Martin SIMA. Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. London: BMJ Publishing Group, 2022, Neuveden., October, p. 1-10. ISSN 2047-9956. Available from: https://dx.doi.org/10.1136/ejhpharm-2022-003535.

@article{2237780,
   author = {Murínová, Irena and Svidrnoch, Martin and Gucky, Tomas and Rezac, David and Hlavac, Jan and Slanar, Ondrej and Sima, Martin},
   article_location = {London},
   article_number = {October},
   doi = {http://dx.doi.org/10.1136/ejhpharm-2022-003535},
   keywords = {critical care; administration; intravenous; drug monitoring; pharmacy service; hospital; practice guideline},
   language = {eng},
   issn = {2047-9956},
   journal = {EUROPEAN JOURNAL OF HOSPITAL PHARMACY},
   title = {Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection},
   url = {https://ejhp.bmj.com/content/early/2022/10/28/ejhpharm-2022-003535},
   volume = {Neuveden.},
   year = {2022}
}

TY  - JOUR
ID  - 2237780
AU  - Murínová, Irena - Svidrnoch, Martin - Gucky, Tomas - Rezac, David - Hlavac, Jan - Slanar, Ondrej - Sima, Martin
PY  - 2022
TI  - Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection
JF  - EUROPEAN JOURNAL OF HOSPITAL PHARMACY
VL  - Neuveden.
IS  - October
SP  - 1-10
EP  - 1-10
PB  - BMJ Publishing Group
SN  - 20479956
KW  - critical care
KW  - administration
KW  - intravenous
KW  - drug monitoring
KW  - pharmacy service
KW  - hospital
KW  - practice guideline
UR  - https://ejhp.bmj.com/content/early/2022/10/28/ejhpharm-2022-003535
N2  - Objectives The objective of this study was to develop a population pharmacokinetic model of meropenem in a heterogeneous population of patients with a serious bacterial infection in order to propose dosing optimisation leading to improved achievement of the pharmacokinetic/pharmacodynamic (PK/PD) target. Methods A total of 174 meropenem serum levels obtained from 144 patients during therapeutic drug monitoring were analysed using a non-linear mixed-effects modelling approach and Monte Carlo simulation was then used to compare various dosing regimens in order to optimise PK/PD target attainment. Results The meropenem volume of distribution of the patient population was 54.95 L, while clearance started at 3.27 L/hour and increased by 0.91 L/hour with each 1 mL/s/1.73 m2 of estimated glomerular filtration rate. Meropenem clearance was also 0.31 L/hour higher in postoperative patients with central nervous system infection. Meropenem administration by continuous infusion showed a significantly higher probability of attaining the PK/PD target than a standard 30 min infusion (95.3% vs 49.5%). Conclusions A daily meropenem dose of 3 g, 6 g and 10.5 g administered by continuous infusion was shown to be accurate for patients with moderate to severe renal impairment, normal renal function to mild renal impairment and augmented renal clearance, respectively
ER  -

MURÍNOVÁ, Irena, Martin SVIDRNOCH, Tomas GUCKY, David REZAC, Jan HLAVAC, Ondrej SLANAR and Martin SIMA. Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection. \textit{EUROPEAN JOURNAL OF HOSPITAL PHARMACY}. London: BMJ Publishing Group, 2022, Neuveden., October, p.~1-10. ISSN~2047-9956. Available from: https://dx.doi.org/10.1136/ejhpharm-2022-003535.

Detailed Information on Publication Record